Bolt Biotherapeutics (BOLT) News Today → Trump’s arrest is phase one (From Porter & Company) (Ad) Free BOLT Stock Alerts $0.76 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 30 at 6:06 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTMay 24, 2024 | investorplace.comThe Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty GrowsMay 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bolt Biotherapeutics, Inc. - BOLTMay 15, 2024 | markets.businessinsider.comBolt Biotherapeutics: Hold Rating Amidst Restructuring and Pipeline UncertaintiesMay 15, 2024 | marketbeat.comSVB Leerink Reaffirms "Market Perform" Rating for Bolt Biotherapeutics (NASDAQ:BOLT)SVB Leerink reiterated a "market perform" rating and set a $1.00 price target (down previously from $3.00) on shares of Bolt Biotherapeutics in a research report on Wednesday.May 15, 2024 | msn.comInvestors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's PremarketMay 15, 2024 | markets.businessinsider.comBolt Biotherapeutics: Hold Rating Amid Clinical Setbacks and High-Risk InnovationsMay 14, 2024 | finance.yahoo.comBolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership TeamMarch 22, 2024 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 21, 2024 | globenewswire.comBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 | globenewswire.comBolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare ConferenceJanuary 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for GlycoMimetics Amidst Phase 3 Progress and Breakthrough Therapy Designation for UproleselanDecember 5, 2023 | finance.yahoo.comBolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®November 11, 2023 | markets.businessinsider.comPromising Clinical Trial Results and Strong Financial Outlook Propel Buy Rating for Bolt BiotherapeuticsNovember 9, 2023 | morningstar.comBolt Biotherapeutics Inc Ordinary Shares BOLTNovember 9, 2023 | finance.yahoo.comBolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 23, 2023 | finance.yahoo.comBolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 CongressOctober 17, 2023 | finance.yahoo.comBolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced CancersSeptember 28, 2023 | finance.yahoo.comBolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric CancersSeptember 5, 2023 | finance.yahoo.comBolt Biotherapeutics to Participate in September Investor ConferencesAugust 3, 2023 | msn.comDynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass EstimatesJune 17, 2023 | finance.yahoo.comUS0977021049.SG - Bolt Biotherapeutics Inc.May 26, 2023 | markets.businessinsider.comBolt Biotherapeutics (BOLT) Receives a Buy from H.C. WainwrightMay 13, 2023 | msn.comSVB Leerink Upgrades Bolt Biotherapeutics (BOLT)May 13, 2023 | msn.comHC Wainwright & Co. Reiterates Bolt Biotherapeutics (BOLT) Buy RecommendationMay 12, 2023 | markets.businessinsider.comJonesTrading Reaffirms Their Buy Rating on Bolt Biotherapeutics (BOLT)May 12, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 26, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual MeetingApril 11, 2023 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 47% over the last yearMarch 30, 2023 | finanznachrichten.deBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 14, 2023 | finance.yahoo.comBolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual MeetingJanuary 21, 2023 | reuters.comBOLT.O - | Stock Price & Latest News | ReutersJanuary 4, 2023 | finance.yahoo.comHere's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn SituationNovember 2, 2022 | finance.yahoo.comInvestors in Bolt Biotherapeutics (NASDAQ:BOLT) have unfortunately lost 89% over the last yearNovember 1, 2022 | finance.yahoo.comBolt Biotherapeutics to Present at Stifel 2022 Healthcare ConferenceSeptember 10, 2022 | morningstar.comBolt Biotherapeutics Inc Ordinary SharesAugust 31, 2022 | finance.yahoo.comBolt Biotherapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceAugust 12, 2022 | benzinga.comBolt Biotherapeutics (NASDAQ:BOLT), Earnings Estimates, EPS, and RevenueMay 26, 2022 | finance.yahoo.comThe past year for Bolt Biotherapeutics (NASDAQ:BOLT) investors has not been profitableMarch 30, 2022 | finance.yahoo.comBolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business HighlightsMarch 30, 2022 | seekingalpha.comBolt Biotherapeutics GAAP EPS of -$0.73 misses by $0.04, revenue of $0.51MMarch 8, 2022 | finance.yahoo.comBolt Biotherapeutics to Present Updates for Three Preclinical Immuno-Oncology Pipeline Programs at AACR Annual Meeting 2022February 10, 2022 | finance.yahoo.comBolt Biotherapeutics, Inc. (BOLT)February 7, 2022 | marketbeat.comBolt Biotherapeutics (NASDAQ:BOLT) Downgraded by Zacks Investment ResearchZacks Investment Research downgraded Bolt Biotherapeutics from a "buy" rating to a "hold" rating in a report on Monday.February 2, 2022 | finance.yahoo.comBolt Biotherapeutics to Participate in Upcoming February ConferencesJanuary 6, 2022 | finance.yahoo.comBolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid TumorsJanuary 6, 2022 | marketbeat.comMorgan Stanley Downgrades Bolt Biotherapeutics (NASDAQ:BOLT) to Equal WeightMorgan Stanley cut shares of Bolt Biotherapeutics from an "overweight" rating to an "equal weight" rating in a research report on Thursday.January 2, 2022 | marketbeat.comBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Given Average Recommendation of "Buy" by AnalystsBolt Biotherapeutics, Inc. (NASDAQ:BOLT) has been assigned a consensus rating of "Buy" from the six analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-yearDecember 11, 2021 | marketwatch.comBolt Biotherapeutics Shares Rise 12% After CFO Buys 5,000 Shares Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address [Urgent!] Generational Wealth Gameplan (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market. Click here to get instant access to the guide BOLT Media Mentions By Week BOLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BOLT News Sentiment▼0.630.78▲Average Medical News Sentiment BOLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BOLT Articles This Week▼20▲BOLT Articles Average Week Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verastem News Curis News Fortress Biotech News SAB Biotherapeutics News Molecular Templates News Amgen News Vertex Pharmaceuticals News Regeneron Pharmaceuticals News Gilead Sciences News Biogen News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BOLT) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProDems have chosen Biden replacement?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
